The serotonin hallucinogen 5-MeO-DMT alters cortico-thalamic activity in freely moving mice: Regionally-selective involvement of 5-HT1A and 5-HT2A receptors
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
&NA; 5‐MeO‐DMT is a natural hallucinogen acting as serotonin 5‐HT1A/5‐HT2A receptor agonist. Its ability to evoke hallucinations could be used to study the neurobiology of psychotic symptoms and to identify new treatment targets. Moreover, recent studies revealed the therapeutic potential of serotonin hallucinogens in treating mood and anxiety disorders. Our previous results in anesthetized animals show that 5‐MeO‐DMT alters cortical activity via 5‐HT1A and 5‐HT2A receptors. Here, we examined 5‐MeO‐DMT effects on oscillatory activity in prefrontal (PFC) and visual (V1) cortices, and in mediodorsal thalamus (MD) of freely‐moving wild‐type (WT) and 5‐HT2A‐R knockout (KO2A) mice. We performed local field potential multi‐recordings evaluating the power at different frequency bands and coherence between areas. We also examined the prevention of 5‐MeO‐DMT effects by the 5‐HT1A‐R antagonist WAY‐100635. 5‐MeO‐DMT affected oscillatory activity more in cortical than in thalamic areas. More marked effects were observed in delta power in V1 of KO2A mice. 5‐MeO‐DMT increased beta band coherence between all examined areas. In KO2A mice, WAY100635 prevented most of 5‐MeO‐DMT effects on oscillatory activity. The present results indicate that hallucinatory activity of 5‐MeO‐DMT is likely mediated by simultaneous alteration of prefrontal and visual activities. The prevention of these effects by WAY‐100635 in KO2A mice supports the potential usefulness of 5‐HT1A receptor antagonists to treat visual hallucinations. 5‐MeO‐DMT effects on PFC theta activity and cortico‐thalamic coherence may be related to its antidepressant activity. This article is part of the Special Issue entitled ‘Psychedelics: New Doors, Altered Perceptions’. Hightlights5‐MeO‐DMT alters cortico‐thalamic activity more in mPFC and V1 than MD thalamus.5‐MeO‐DMT augments beta band coherence between cortico‐thalamic areas.5‐HT1A‐R antagonism avoids 5‐MeO‐DMT actions in KO2A mice.Increase in PFC theta band by 5‐MeO‐DMT may be related to its antidepressant effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abnormal neural oscillations and synchrony in schizophrenia
Uhlhaas, P. J., & Singer, W. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2774 · Cited by 2,120 · cited 1×
“Alterations in oscillatory activity have been associated with psychiatric disorders such as schizophrenia (Uhlhaas and Singer, 2010) and depression (Clark et al.”
BackgroundMeditation states and traits: EEG, ERP, and neuroimaging studies.
Cahn, B. R., & Polich, J. (2006) · Psychological Bulletin · doi:10.1037/0033-2909.132.2.180 · Cited by 1,734 · cited 1×
“, 2017) and meditation (Cahn and Polich, 2006) increase frontal theta activity.”
BackgroundCarhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 3×
“…NMDA-R antagonist such as ketamine (Monteggia and Zarate, 2015; Zarate et al., 2006) and serotonergic hallucinogens such as psilocybin (Carhart-Harris et al., 2016a) show clinical efficacy in depressed patients resistant to other forms of treatment (Baumeister et al., 2014;…”
Grouping of brain rhythms in corticothalamic systems
Steriade, M. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2005.10.029 · Cited by 1,296
Prefrontal cortex in the rat: Projections to subcortical autonomic, motor, and limbic centers
Gabbott, P. L. A., Warner, T. A., Jays, P. R. L., Salway, P., & Busby, S. J. (2005) · Journal of Comparative Neurology · doi:10.1002/cne.20738 · Cited by 1,227 · cited 2×
“As discussed above, coherence between mPFC and MD thalamus was the most affected coherence, probably due to the dense and reciprocal cortico-thalamic connectivity between these two areas (Gabbott et al., 2005; Groenewegen and Uylings, 2000).”
BackgroundNichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172 · cited 1×
“Recently, clinical studies reported the efficacy of psilocybin for treatment-resistant depression, an effect perhaps related to activity changes of thalamic and PFC areas, as reported in fMRI studies (Carhart-Harris et al., 2012) and to themodulation in the oscillatory activity observed on EEG (Kometer et al.”
BackgroundPsilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018 · cited 1×
“5-HT1A-R and 5-HT2A-Rs are involved in the behavioral and electrophysiological effects of hallucinogenic drugs and in the regulation of sensorimotor gating (Gonzalez-Maeso et al., 2007; Krebs-Thomson et al., 2006; van den Buuse et al., 2011; Vollenweider et al., 1998; Winter et al., 2000).”
BackgroundGonzález-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925 · cited 2×
“Preclinical and clinical evidence support that the psychotomimetic action of these hallucinogens is, at least, partially mediated by their agonistic actions at cortical 5-HT2A-R (Gonzalez-Maeso et al., 2007; Nichols, 2004).”
BackgroundNeural correlates of the LSD experience revealed by multimodal neuroimaging
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., Tagliazucchi, E., Schenberg, E. E., Nest, T., Orban, C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518377113 · Cited by 859 · cited 3×
“…NMDA-R antagonist such as ketamine (Monteggia and Zarate, 2015; Zarate et al., 2006) and serotonergic hallucinogens such as psilocybin (Carhart-Harris et al., 2016a) show clinical efficacy in depressed patients resistant to other forms of treatment (Baumeister et al., 2014;…”
Identification of a serotonin/glutamate receptor complex implicated in psychosis
González-Maeso, J., Ang, R. L., Yuen, T., Chan, P., Weisstaub, N. V., López-Giménez, J. F., Zhou, M., Okawa, Y., Callado, L. F., Milligan, G., et al. (2008) · Nature · doi:10.1038/nature06612 · Cited by 803
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723 · cited 3×
“Similar actions have been reported after ketamine administration (Vollenweider and Kometer, 2010), a non-competitive NMDA-R antagonist with proven efficacy in treatment-resistant depression (Zarate et al.”
BackgroundResultThalamic Mechanisms of EEG Alpha Rhythms and Their Pathological Implications
Hughes, S. W., & Crunelli, V. (2005) · The Neuroscientist · doi:10.1177/1073858405277450 · Cited by 565
Increased global functional connectivity correlates with LSD-induced ego dissolution
Tagliazucchi, E., Roseman, L., Kaelen, M., Orban, C., Muthukumaraswamy, S. D., Murphy, K., Laufs, H., Leech, R., McGonigle, J., Crossley, N., et al. (2016) · Current Biology · doi:10.1016/j.cub.2016.02.010 · Cited by 503 · cited 1×
“, 2005a) whereas antidepressant treatment and LSD increase cortico-thalamic connectivity (Anand et al., 2005b; Tagliazucchi et al., 2016).”
BackgroundSantana, N. (2004) · Cerebral Cortex · doi:10.1093/cercor/bhh070 · Cited by 486 · cited 2×
“The effects of 5-MeO-DMT were more marked in V1 and mPFC than in MD thalamus, consistent with the high density of 5-HT1A-R and 5-HT2A-R in these cortical areas and their absence in thalamic nuclei (Pompeiano et al., 1992, 1994; Santana et al., 2004).”
BackgroundResultSanches, R. F., de Lima Osório, F., dos Santos, R. G., Macedo, L. R. H., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000436 · Cited by 466 · cited 1×
“Likewise, several studies have reported antidepressant efficacy of Ayahuasca, containing dimethyltryptamines in varying proportions (Sanches et al., 2016).”
BackgroundPalhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J. A. S., Hallak, J. E. C., Ribeiro, S., & de Araujo, D. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118143 · Cited by 454
Vollenweider, F. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00246-1 · Cited by 444 · cited 1×
“Moreover, psychedelic agents are used to model certain aspects of psychosis in experimental research (Geyer and Vollenweider, 2008), helping also to identify brain circuits altered in psychiatric disorders (Vollenweider et al., 1997).”
BackgroundSerotonin research: contributions to understanding psychoses
GEYER, M., & VOLLENWEIDER, F. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.06.006 · Cited by 427
Amargos-Bosch, M. (2004) · Cerebral Cortex · doi:10.1093/cercor/bhg128 · Cited by 370
Antidepressant Effect on Connectivity of the Mood-Regulating Circuit: An fMRI Study
Anand, A., Li, Y., Wang, Y., Wu, J., Gao, S., Bukhari, L., Mathews, V. P., Kalnin, A., & Lowe, M. J. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300725 · Cited by 324
McKenna, D. J. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.03.002 · Cited by 321
Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease
Ballanger, B., Strafella, A. P., van Eimeren, T., Zurowski, M., Rusjan, P. M., Houle, S., & Fox, S. H. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.35 · Cited by 266 · cited 1×
“, 2010) and altered expression has been reported in patients with visual hallucinations and untreated schizophrenic subjects (Ballanger et al., 2010; GonzalezMaeso et al., 2008).”
BackgroundSeeing with the eyes shut: neural basis of enhanced imagery following ayahuasca ingestion.
de Araujo, D. B., Ribeiro, S., Cecchi, G. A., Carvalho, F. M., Sanchez, T. A., Pinto, J. P., de Martinis, B. S., Crippa, J. A., Hallak, J. E. C., & Santos, A. C. (2012) · Human Brain Mapping · doi:10.1002/hbm.21381 · Cited by 239
Halberstadt, A. L., Koedood, L., Powell, S. B., & Geyer, M. A. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110388326 · Cited by 213
Valle, M., Maqueda, A. E., Rabella, M., Rodríguez-Pujadas, A., Antonijoan, R. M., Romero, S., Alonso, J. F., Mañanas, M. À., Barker, S., Friedlander, P., et al. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.03.012 · Cited by 173
Shen, H.-W., Jiang, X.-L., C. Winter, J., & Yu, A.-M. (2010) · Current Drug Metabolism · doi:10.2174/138920010794233495 · Cited by 170
Llado-Pelfort, L., Santana, N., Ghisi, V., Artigas, F., & Celada, P. (2012) · Cerebral Cortex · doi:10.1093/cercor/bhr220 · Cited by 156 · cited 1×
“, unpublished results) and increased pyramidal neuron discharge in anesthetized rats, through a preferential action on 5-HT1A-R located on fast-spiking GABAergic interneurons (Llado-Pelfort et al., 2012).”
ResultSelf-citationAntidepressant actions of ketamine: from molecular mechanisms to clinical practice
Monteggia, L. M., & Zarate, C. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2014.12.004 · Cited by 149
Riba, J., Anderer, P., Morte, A., Urbano, G., Jané, F., Saletu, B., & Barbanoj, M. J. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01609.x · Cited by 125 · cited 4×
“, 1993), and the preferential 5-HT2A-R agonists DMT and psilocybin decrease delta power (Muthukumaraswamy et al., 2013; Riba et al., 2002).”
BackgroundInfluentialSerotonin and molecular neuroimaging in humans using PET
Saulin, A., Savli, M., & Lanzenberger, R. (2012) · Amino Acids · doi:10.1007/s00726-011-1078-9 · Cited by 113 · cited 1×
“5-HT2A-R and 5-HT1A-R are expressed in the visual cortex (Dyck and Cynader, 1993; Gerstl et al., 2008; Moreau et al., 2010; Saulin et al., 2012; Watakabe et al., 2009).”
BackgroundMcKenna, D., & Peroutka, S. (1989) · The Journal of Neuroscience · doi:10.1523/jneurosci.09-10-03482.1989 · Cited by 103
Serotonergic psychedelics temporarily modify information transfer in humans.
Alonso, J. F., Romero, S., Mañanas, M. À., & Riba, J. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv039 · Cited by 101
Watakabe, A., Komatsu, Y., Sadakane, O., Shimegi, S., Takahata, T., Higo, N., Tochitani, S., Hashikawa, T., Naito, T., Osaki, H., et al. (2009) · Cerebral Cortex · doi:10.1093/cercor/bhn219 · Cited by 93 · cited 1×
“5-HT2A-R and 5-HT1A-R are expressed in the visual cortex (Dyck and Cynader, 1993; Gerstl et al., 2008; Moreau et al., 2010; Saulin et al., 2012; Watakabe et al., 2009).”
BackgroundKikuchi, M., Hashimoto, T., Nagasawa, T., Hirosawa, T., Minabe, Y., Yoshimura, M., Strik, W., Dierks, T., & Koenig, T. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.06.003 · Cited by 74 · cited 1×
“, 2006), or during resting state (increases) (Kikuchi et al., 2011) when compared with control subjects.”
Cited by
Towards an understanding of psychedelic-induced neuroplasticity
Calder, A. E., & Hasler, G. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01389-z · Cited by 313
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Onofrj, M., Russo, M., Delli Pizzi, S., De Gregorio, D., Inserra, A., Gobbi, G., & Sensi, S. L. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02691-0 · Cited by 43
Barsuglia, J. P., Polanco, M., Palmer, R., Malcolm, B. J., Kelmendi, B., & Calvey, T. (2018) · Progress in Brain Research · doi:10.1016/bs.pbr.2018.08.002 · Cited by 38
How do serotonergic psychedelics treat depression: The potential role of neuroplasticity
Artin, H., Zisook, S., & Ramanathan, D. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i6.201 · Cited by 33
Metadata
- Authors
- Riga, M. S., Lladó-Pelfort, L., Artigas, F., & Celada, P.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2018-11
- Volume
- 142
- Pages
- 219-230
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2773072410
- Cited by
- 53
- References
- 35
- FWCI
- 3.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.